AbbVie accuses rival of stealing blockbuster ‘trade secrets’ as clock ticks down on biosimilar assault
Two years before the first biosimilars to megablockbuster Humira are expected to hit the US market, AbbVie is taking one developer to court over allegations …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.